相似文献
1
Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.
Cancer Discov. 2015 Apr;5(4):348-50. doi: 10.1158/2159-8290.CD-15-0221.
2
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.
3
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461. doi: 10.1073/pnas.1610456113. Epub 2016 Nov 9.
4
Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Oncotarget. 2017 Jan 17;8(3):5003-5015. doi: 10.18632/oncotarget.14009.
5
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Oncogene. 2018 Jun;37(24):3183-3199. doi: 10.1038/s41388-018-0171-x. Epub 2018 Mar 15.
6
Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF mutant cancer.
Life Sci. 2017 Aug 15;183:37-44. doi: 10.1016/j.lfs.2017.06.021. Epub 2017 Jun 21.
7
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Oncotarget. 2017 Feb 7;8(6):9251-9266. doi: 10.18632/oncotarget.14002.
8
Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.
Int J Mol Sci. 2017 Mar 8;18(3):585. doi: 10.3390/ijms18030585.
9
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Mol Cancer Res. 2017 Oct;15(10):1431-1444. doi: 10.1158/1541-7786.MCR-17-0211. Epub 2017 Jun 27.
10
MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
Eur J Cancer. 2017 Mar;73:93-101. doi: 10.1016/j.ejca.2016.12.012. Epub 2017 Feb 3.
引用本文的文献
1
Ring finger protein 215 is a potential prognostic biomarker involved in immune infiltration and angiogenesis in colorectal cancer.
Biomed Rep. 2023 Jun 12;19(1):50. doi: 10.3892/br.2023.1633. eCollection 2023 Jul.
2
Autocrine/paracrine actions of growth hormone in human melanoma cell lines.
Biochem Biophys Rep. 2019 Dec 18;21:100716. doi: 10.1016/j.bbrep.2019.100716. eCollection 2020 Mar.
3
MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer.
Cancer Res. 2019 Nov 15;79(22):5812-5825. doi: 10.1158/0008-5472.CAN-19-0698. Epub 2019 Jul 30.
4
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.
Cancer Discov. 2017 Aug;7(8):832-851. doi: 10.1158/2159-8290.CD-16-0955. Epub 2017 Apr 28.
5
PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
Oncotarget. 2016 Dec 13;7(50):83017-83030. doi: 10.18632/oncotarget.12940.
本文引用的文献
1
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.
2
Novel therapeutic options for relapsed hairy cell leukemia.
Leuk Lymphoma. 2015;56(8):2264-72. doi: 10.3109/10428194.2014.1001988. Epub 2015 Feb 4.
3
Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
Mol Cancer Ther. 2015 Feb;14(2):542-52. doi: 10.1158/1535-7163.MCT-14-0723. Epub 2014 Dec 4.
4
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
5
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27.
6
Tumor adaptation and resistance to RAF inhibitors.
Nat Med. 2013 Nov;19(11):1401-9. doi: 10.1038/nm.3392.
7
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.
Zotero 插件